Compare MRBK & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MRBK | MDXH |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.1M | 183.4M |
| IPO Year | 2018 | 2021 |
| Metric | MRBK | MDXH |
|---|---|---|
| Price | $19.89 | $3.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $20.00 | $7.67 |
| AVG Volume (30 Days) | 81.8K | ★ 111.3K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $5,735,000.00 | N/A |
| Revenue This Year | $25.40 | $23.34 |
| Revenue Next Year | $8.15 | $22.98 |
| P/E Ratio | $15.60 | ★ N/A |
| Revenue Growth | ★ 16.38 | N/A |
| 52 Week Low | $11.17 | $1.35 |
| 52 Week High | $21.03 | $5.33 |
| Indicator | MRBK | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 54.83 |
| Support Level | $19.76 | $3.45 |
| Resistance Level | $20.66 | $3.80 |
| Average True Range (ATR) | 0.59 | 0.20 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 59.41 | 75.00 |
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.